Trial Profile
Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azeliragon (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms STEADFAST
- Sponsors vTv Therapeutics LLC.
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020
- 15 Jul 2019 According to vTv Therapeutics media release, data from this study will be presented at the 2019 Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, July 14 to 18, 2019.
- 28 Mar 2019 According to a vTv Therapeutics LLC media release, results from this trial will be presneted at the 14th International Conference on Alzheimer's & Parkinson's Diseases.